Eligibility
Applicants must be employed by an institution engaged in health-related research. Applicants must agree to always be supervised by the institution while conducting research supported by FCF. If a change in institution is made while applying for, or utilizing funds from FCF, applicants must notify FCF. Continuation of the grant award will be subject to review based upon the change in circumstances.
The research must focus on Fibrolamellar Carcinoma (FLC) [also known as Fibrolamellar Hepatocellular Carcinoma (FL-HCC)]. Studies should be intended to advance the understanding, diagnosis, epidemiology, or treatment of FLC. Of particular interest are applications showing a clear path towards novel therapies / clinical trials with the eventual goal of achieving a cure for FLC. FCF will accept grant applications to support innovative and promising research projects towards the above goals.
Collaboration and open sourcing are a requirement for funding by FCF and will be specified in any grant agreement. FCF believes that collaboration among multiple teams and institutions, together with early sharing of data and resources, often accelerates the path to a cure for rare cancers.